Management of complicated urinary tract infections in the era of antimicrobial resistance

Postgraduate Medicine

Volumn 122, Issue 6, 2010, Pages 7-15

  Bader, Mazen S ^a   Hawboldt, John ^b   Brooks, Annie ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Antimicrobial resistance; Complicated urinary tract infections; Escherichia coli; Extended spectrum lactamases; Fluoroquinolones

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFALEXIN; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; FOSFOMYCIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NITROFURANTOIN; NORFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TRIMETHOPRIM; TROMETAMOL; UNINDEXED DRUG; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COMPLICATED URINARY TRACT INFECTION; CYSTITIS; DRUG ELIMINATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ESCHERICHIA COLI; HUMAN; MICROBIOLOGY; NONHUMAN; RECOMMENDED DRUG DOSE; TREATMENT DURATION; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; MICROBIOLOGICAL EXAMINATION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTIONS;

EID: 79952199427     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.11.2217     Document Type: Article

References (66)

1. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: a population-based assessment. Infection. 2007;35(3):150-153.
2. Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control. 2009;37(10):783-805.
3. Al-Hasan MN, Eckel-Passow JE, Baddour LM. Bacteremia complicating gram-negative urinary tract infections: a population-based study. J Infect. 2010;60(4):278-285.
4. Katsarolis I, Poulakou G, Athanasia S, et al; Collaborative Study Group on Antibiotic Resistance in Community-acquired Urinary Tract Infections. Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. Int J Antimicrob Agents. 2010;35(1):62-67.
5. Koeijers JJ, Verbon A, Kessels AG, et al. Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility. Urology. 2010;76(2):336-340.
6. Hooton TM, Bradley SF, Cardenas DD, et al; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625-663.
7. Johansen TE, Cek M, Naber KG, Stratchounski L, Svendsen MV, Tenke P; PEP and PEAP-study investigators; Board of the European Society of Infections in Urology. Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int J Antimicrob Agents. 2006;28(suppl 1):S91-S107.
8. Shigemura K, Arakawa S, Tanaka K, Fujisawa M. Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics. J Infect Chemother. 2009;15(1):18-22.
9. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45(12):1602-1609.
10. Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006. Clin Ther. 2007;29(10):2215-2221.
11. Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002;287(20):2701-2710.
12. Schmiemann G, Kniehl E, Gebhardt K, Matejczyk MM, Hummers-Pradier E. The diagnosis of urinary tract infection: a systematic review. Dtsch Arztebl Int. 2010;107(21):361-367.
13. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med. 2000;160(5):678-682.
14. The prevention and management of urinary tract infections among people with spinal cord injuries. National Institute on Disability and Rehabilitation Research Consensus Statement. 27-29 January 1992. J Am Paraplegia Soc. 1992;15(3):194-204.
15. Lammers RL, Gibson S, Kovacs D, Sears W, Strachan G. Comparison of test characteristics of urine dipstick and urinalysis at various test cutoff points. Ann Emerg Med. 2001;38(5):505-512.
16. Kunin CM, White LV, Hua TH. A reassessment of the importance of "low-count" bacteriuria in young women with acute urinary symptoms. Ann Intern Med. 1993;119(6):454-460.
17. Velasco M, Martinez JA, Moreno-Martinez A, et al. Blood cultures for women with uncomplicated acute pyelonephritis: are they necessary? Clin Infect Dis. 2003;37(8):1127-1130.
18. Hsu CY, Fang HC, Chou KJ, Chen CL, Lee PT, Chung HM. The clinical impact of bacteremia in complicated acute pyelonephritis. Am J Med Sci. 2006;332(4):175-180.
19. Chen Y, Nitzan O, Saliba W, Chazan B, Colodner R, Raz R. Are blood cultures necessary in the management of women with complicated pyelonephritis? J Infect. 2006;53(4):235-240.
20. Demertzis J, Menias CO. State of the art: imaging of renal infections. Emerg Radiol. 2007;14(1):13-22.
21. Taneja N, Rao P, Arora J, Dogra A. Occurrence of ESBL and Amp-C beta lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res. 2008;127(1):85-88.
22. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ; EMERGEncy ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole-and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. 2008;47(9):1150-1158.
23. Blaettler L, Mertz D, Frei R, et al. Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007. Infection. 2009;37(6):534-549.
24. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother. 2009;64(1):169-174.
25. Das R, Perrelli E, Towle V, Van Ness PH, Juthani-Mehta M. Antimicrobial susceptibility of bacteria isolated from urine samples obtained from nursing home residents. Infect Control Hosp Epidemiol. 2009;30(11):1116-1119.
26. Vellinga A, Murphy AW, Hanahoe B, Bennett K, Cormican M. A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother. 2010;65(7):1514-1520.
27. Urban C, Mariano N, Bradford PA, Tuckman M, Segal-Maurer S, Wehbeh W. Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis. 2010;66(4):402-406.
28. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis. 2010;51(3):286-294.
29. Qi C, Pilla V, Yu JH, Reed K. Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008. Diagn Microbiol Infect Dis. 2010;67(1):87-91.
30. Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313-333.
31. Warburg G, Korem M, Robicsek A, et al. Changes in aac(6')-Ib-cr prevalence and fluoroquinolone resistance in nosocomial isolates of Escherichia coli collected from 1991 through 2005. Antimicrob Agents Chemother. 2009;53(3):1268-1270.
32. Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12(1):83-88.
33. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161-182.
34. Pitout JD, Gregson DB, Church DL, Laupland KB. Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis. 2007;13(3):443-448.
35. Chan JD, Graves JA, Dellit TH. Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia [published online ahead of print September 13, 2010]. J Intensive Care Med.
36. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597-602.
37. Centers for Disease Control and Prevention (CDC). Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase-United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(24):750.
38. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65(6):1119-1125.
39. Wagenlehner FM, Weidner W, Perletti G, Naber KG. Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2010;15(3):375-397.
40. Wagenlehner FM, Naber KG. Current challenges in the treatment of complicated urinary tract infections and prostatitis. Clin Microbiol Infect. 2006;12(suppl 3):67-80.
41. Hermanides HS, Hulscher ME, Schouten JA, Prins JM, Geerlings SE. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. Clin Infect Dis. 2008;46(5):703-711.
42. Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clinic Proc. 2004;79(8):1048-1054.
43. Matsumoto T, Muratani T. Newer carbapenems for urinary tract infections. Int J Antimicrob Agents. 2004;24(suppl 1):S35-S38.
44. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drug. 2007;67(7):1027-1052.
45. Baughman RP. The use of carbapenems in the treatment of serious infections. J Intensive Care Med. 2009;24(4):230-241.
46. Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized double blind multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004;53(suppl 2):ii67-ii74.
47. Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J Antimicrob Chemother. 2010;65(7):1510-1513.
48. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther. 2009;31(1):42-63.
49. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams with an option to switch to oral therapy for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother. 2009;53(9):3782-3792.
50. Bolon MK. The newer fluoroquinolones. Infect Dis Clin North Am. 2009;23(4):1027-1051.
51. Ryan RJ, Lindsell C, Sheehan P. Fluoroquinolone resistance during 2000-2005: an observational study. BMC Infect Dis. 2008;8:71.
52. Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol. 2004;171(2 pt 1):734-739.
53. Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007;23(11):2637-2645.
54. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71(1):17-22.
55. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68(4):535-565.
56. McGregor JC, Allen GP, Bearden DT. Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Ther Clin Risk Manag. 2008;4(5):843-853.
57. Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother. 2001;48(1):37-45.
58. Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Int J Antimicrob Agents. 2008;32(4):320-325.
59. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli infection. Infection. 2008;36(1):41-45.
60. Maviglia R, Nestorini R, Pennisi M. Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets. 2009;10(9):895-905.
61. Krueger WA, Kempt VA, Peiffer M, et al. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-β-lactamase-producing Escherichia coli. J Clin Microbiol. 2008;46(2):817-820.
62. Nix DE, Matthias KR. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother. 2010;65(6):1311-1312.
63. Kashanian J, Hakimian P, Blute M Jr, et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int. 2008;102(11):1634-1637.
64. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43-50.
65. Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez-Ruiz R, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother. 2009;64(4):712-717.
66. Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother. 2009;10(5):785-796.